CA2306790A1 - Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques - Google Patents
Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques Download PDFInfo
- Publication number
- CA2306790A1 CA2306790A1 CA002306790A CA2306790A CA2306790A1 CA 2306790 A1 CA2306790 A1 CA 2306790A1 CA 002306790 A CA002306790 A CA 002306790A CA 2306790 A CA2306790 A CA 2306790A CA 2306790 A1 CA2306790 A1 CA 2306790A1
- Authority
- CA
- Canada
- Prior art keywords
- tnf
- serum level
- interleukin
- antagonists
- tnf antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Utilisation d'antagonistes du TNF pour la préparation de médicaments destinés à traiter les maladies septiques caractérisées par une augmentation du taux sérique d'interleukine-6 pendant un intervalle de mesure d'au moins trente minutes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19746868A DE19746868A1 (de) | 1997-10-23 | 1997-10-23 | Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen |
DE19746868.3 | 1997-10-23 | ||
PCT/EP1998/006545 WO1999021582A2 (fr) | 1997-10-23 | 1998-10-15 | Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2306790A1 true CA2306790A1 (fr) | 1999-05-06 |
Family
ID=7846420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002306790A Abandoned CA2306790A1 (fr) | 1997-10-23 | 1998-10-15 | Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1024831A2 (fr) |
JP (1) | JP2001521009A (fr) |
KR (1) | KR20010024549A (fr) |
CN (1) | CN1163272C (fr) |
AU (1) | AU756167B2 (fr) |
BR (1) | BR9813114A (fr) |
CA (1) | CA2306790A1 (fr) |
DE (1) | DE19746868A1 (fr) |
HU (1) | HUP0100105A3 (fr) |
IL (1) | IL135083A0 (fr) |
NO (1) | NO20001894D0 (fr) |
WO (1) | WO1999021582A2 (fr) |
ZA (1) | ZA989615B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
UA76639C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
UA76640C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб |
RU2309732C1 (ru) | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
KR101901465B1 (ko) | 2010-07-15 | 2018-09-21 | 올레그 일리치 엡쉬테인 | 위장관의 기능적 질환 또는 상태를 치료하는 제약학적 복합 조성물 및 방법들 |
SG187038A1 (en) | 2010-07-15 | 2013-02-28 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
EP2415461B1 (fr) * | 2010-07-24 | 2012-10-31 | Roche Diagnostics GmbH | Stabilisation d'interleukine 6 dans des solutions à base de sérum |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2638652B2 (ja) * | 1988-07-18 | 1997-08-06 | カイロン・コーポレーション | カケクチンと反応するモノクロナール抗体 |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
-
1997
- 1997-10-23 DE DE19746868A patent/DE19746868A1/de not_active Withdrawn
-
1998
- 1998-10-15 KR KR1020007004361A patent/KR20010024549A/ko not_active Application Discontinuation
- 1998-10-15 CA CA002306790A patent/CA2306790A1/fr not_active Abandoned
- 1998-10-15 IL IL13508398A patent/IL135083A0/xx unknown
- 1998-10-15 EP EP98955459A patent/EP1024831A2/fr not_active Withdrawn
- 1998-10-15 HU HU0100105A patent/HUP0100105A3/hu unknown
- 1998-10-15 JP JP2000517740A patent/JP2001521009A/ja active Pending
- 1998-10-15 CN CNB988105144A patent/CN1163272C/zh not_active Expired - Fee Related
- 1998-10-15 BR BR9813114-1A patent/BR9813114A/pt not_active IP Right Cessation
- 1998-10-15 AU AU12284/99A patent/AU756167B2/en not_active Withdrawn - After Issue
- 1998-10-15 WO PCT/EP1998/006545 patent/WO1999021582A2/fr not_active Application Discontinuation
- 1998-10-22 ZA ZA9809615A patent/ZA989615B/xx unknown
-
2000
- 2000-04-12 NO NO20001894A patent/NO20001894D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU756167B2 (en) | 2003-01-09 |
CN1277556A (zh) | 2000-12-20 |
JP2001521009A (ja) | 2001-11-06 |
HUP0100105A2 (hu) | 2001-05-28 |
ZA989615B (en) | 2000-04-20 |
IL135083A0 (en) | 2001-05-20 |
HUP0100105A3 (en) | 2003-08-28 |
AU1228499A (en) | 1999-05-17 |
WO1999021582A3 (fr) | 1999-07-15 |
KR20010024549A (ko) | 2001-03-26 |
CN1163272C (zh) | 2004-08-25 |
DE19746868A1 (de) | 1999-04-29 |
NO20001894L (no) | 2000-04-12 |
EP1024831A2 (fr) | 2000-08-09 |
NO20001894D0 (no) | 2000-04-12 |
WO1999021582A2 (fr) | 1999-05-06 |
BR9813114A (pt) | 2000-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6235281B1 (en) | Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 | |
US20030012786A1 (en) | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients | |
EP0966300B1 (fr) | Traitement de la polyarthrite rhumatoide avec un anticorps anti ifn gamma | |
US20030161828A1 (en) | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure | |
US5888510A (en) | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component | |
EP0783893B1 (fr) | Inhibition de la croissance anormale de cellules synoviales a l' aide d' un antagoniste d'interleukine 6 comme principe actif | |
US7504106B2 (en) | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis | |
RU2607022C2 (ru) | Способы и композиции для лечения волчанки | |
WO2005079848A9 (fr) | Procedes de modulation de l'activite de la cytokine, et reactifs connexes | |
JP2017031209A (ja) | アタシセプトなどのTACI−Ig融合タンパク質を用いた自己免疫疾患を治療するための投薬法 | |
AU756167B2 (en) | Application of TNF antagonists as medicaments for treating septic diseases | |
JP2002501902A (ja) | リンホトキシン(lt)経路のインヒビターを使用する濾胞性リンパ腫の処置 | |
JP2003531822A (ja) | 自己免疫疾患を治療するためのth−1免疫反応誘導サイトカインの拮抗薬 | |
JP4827352B2 (ja) | Il−18阻害剤の用途 | |
KR100414505B1 (ko) | 높은혈청수준의인터류킨-6을갖는질환을치료하기위한약물로서의항-tnf항체의용도 | |
MXPA00003355A (en) | Application of tnf antagonists as medicaments for treating septic diseases | |
AU5394001A (en) | The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 | |
CZ20001407A3 (cs) | Použití TNF antagonistů pro výrobu drog k léčení septických poruch | |
AU1549599A (en) | The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of the interleukin-6 | |
AU732764B2 (en) | Rheumatoid arthritis remedy containing IL-6 antagonist as effective component | |
AU2005232321A1 (en) | Methods and compositions for treating IgE-related disease using NNT-1-inhibitors | |
JPH07258112A (ja) | インターロイキン−6血清濃度上昇症状を示す疾病の治療のための薬剤 | |
RU2000112873A (ru) | Применение антагонистов фактора опухолевого некроза для получения лекарственных средств для лечения септических болезней |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |